Yes, magnesium sulfate and calcium should be routinely added to pediatric TPN, but calcium gluconate in glass vials should NOT be used.
Both magnesium and calcium are essential components that must be included in pediatric parenteral nutrition to ensure optimal growth and bone mineralization, with specific age-based dosing requirements. 1
Mandatory Inclusion with Specific Dosing
The ESPGHAN/ESPEN/ESPR/CSPEN 2018 guidelines provide clear, age-stratified recommendations for routine inclusion 1:
Magnesium Sulfate Dosing (mmol/kg/day):
- Preterm infants (first days): 0.1-0.2
- Growing preterm infants: 0.2-0.3
- Term infants 0-6 months: 0.1-0.2
- 7-12 months: 0.15
- 1-18 years: 0.1
Calcium Dosing (mmol/kg/day):
- Preterm infants (first days): 0.8-2.0
- Growing preterm infants: 1.6-3.5
- Term infants 0-6 months: 0.8-1.5
- 7-12 months: 0.5
- 1-18 years: 0.25-0.4
Critical Safety Considerations for Calcium Source
Calcium gluconate stored in glass vials is contaminated with aluminum and should NOT be used in PN (strong recommendation) 1. This is particularly dangerous in pediatric patients where aluminum toxicity risk is elevated 2. Instead:
- Use calcium gluconate packaged in polyethylene containers to minimize aluminum contamination 1
- Aluminum intake must not exceed 5 mg/kg/day 1
- Organic calcium salts (calcium gluconate in polyethylene or calcium glycerophosphate) are strongly recommended over inorganic salts to prevent precipitation 1
Magnesium Sulfate: The Preferred Form
Magnesium sulfate is the standard form used in pediatric PN 1. The FDA label confirms its indication for TPN to correct or prevent hypomagnesemia, with maintenance doses of 2-10 mEq (0.25-1.25 g) daily for infants 3. Magnesium chloride should be avoided as it increases anion gap and metabolic acidosis risk 1.
Special Populations Requiring Dose Adjustment
Preterm Infants Exposed to Maternal Magnesium:
- Mothers receiving magnesium sulfate for preeclampsia/tocolysis can cause neonatal hypermagnesemia 1
- Low postnatal glomerular filtration rates limit magnesium excretion in the first week 1
- Adapt magnesium doses based on serum levels in these infants 1
Growth-Restricted Preterm Infants:
- At high risk for severe hypophosphatemia when protein/energy are optimized 1
- Requires careful phosphate monitoring to prevent muscle weakness, respiratory failure, cardiac dysfunction, and death 1
- Use lower Ca:P molar ratios (0.8-1.0) in early PN to reduce hypercalcemia/hypophosphatemia risk 1
Precipitation Prevention Algorithm
When adding both calcium and magnesium to PN 1:
- Use organic salts (calcium gluconate in polyethylene + organic phosphate sources) 1
- Mixing sequence matters: Mix calcium salt with amino acids and glucose FIRST, then dilute, add phosphate LAST 1
- Test stability with local pharmacy when using upper-range calcium/phosphate doses 1
- Dilute to ≤20% concentration before administration 3
Monitoring Requirements
Regular monitoring is mandatory (strong recommendation) 1:
- Serum calcium, phosphorus, magnesium, and alkaline phosphatase
- Urine calcium and phosphorus concentrations
- Target: simultaneous urinary excretion of both Ca and P >1 mmol/L indicates adequate intake 1
Clinical Rationale
Growth is the primary determinant of mineral requirements in pediatrics 1. Fetal accretion data shows 0.21 mmol Ca/g and 0.15 mmol P/g body weight 1. Failure to provide adequate calcium, phosphorus, and magnesium leads to metabolic bone disease, osteopenia, and impaired growth 1. Recent evidence confirms safety when providing median magnesium of 0.2-0.3 mmol/kg/day in full-term neonates and children up to 24 months 4.